Arthrogen   Report issue

For profit Phase 1
Founded: Amsterdam Netherlands (2005)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2017
NCT02727764
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Arthrogen